The evolution of CLL treatment
28 Apr 2015
The evolution of CLL treatment
New T cell–based immunotherapy shows promise for lethal stem cell transplant complication
DNA repair inhibitors to overcome drug resistance
Putting adoptive T cell therapy on the path to regulatory approval
New drugs and targets in haematological malignancies
ecancermedicalscience editor's choice for February 2015
ASCO GU 2015 news roundup
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction
mRCC: Are we doing all we can to manage adverse events?
mRCC: Real-world experience: achieving efficacy beyond clinical trials
mRCC: Understanding the patient's perspective
mRCC: Closing remarks